Author

Luca Aresu

Institute of Oncology ResearchORCID 0000-0002-7893-1740Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Alberto J. ArribasiD· 2 shared Anastasios StathisiD· 2 shared Chiara TarantelliiD· 2 shared Eleonora CannasiD· 2 shared Francesco BertoniiD· 2 shared Luciano CascioneiD· 2 shared Andrea CavalliiD· 1 shared Andrea RinaldiiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alberto J. ArribasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 23, 2025

The anti-metabolite KAT/3BP has in vitro and in vivo anti-tumor activity in lymphoma models

Chiara Tarantelli, Filippo Spriano, Elisa Civanelli…·Francesco Bertoni

This study evaluates KAT/3BP, a 3BP derivative, showing in vitro and in vivo anti-tumor activity against lymphoma models, including resistant cell lines and synergistic effects with existing therapies.

DOI 10.1101/2025.04.23.650181

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyBlood AdvancesPeer-reviewedOct 7, 2024

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

Alberto J. Arribas, Sara Napoli, Eugenio Gaudio…·Francesco Bertoni

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

12 citations

humanproteomics

𝕏 PostBluesky